SOPHiA GENETICS and Strand Life Sciences Forge Fresh Strategic Alliance
Friday, April 05, 2024
SOPHiA GENETICS (Nasdaq: SOPH), a prominent player in the healthcare technology sector focusing on data-driven medicine, has unveiled a strategic collaboration with Strand Life Sciences. This partnership aims to introduce groundbreaking solutions to drive the global adoption of precision medicine. By combining the strengths of both entities, the collaboration will grant access to cutting-edge genomics technologies, bioinformatics services, and diagnostic solutions.
Headquartered in Bangalore, India, Strand Life Sciences is recognized for its expertise in bioinformatics, laboratory assays, clinical research, and software development. Through its tailor-made applications, Strand aids a diverse global clientele, facilitating the expansion and enhancement of precision medicine on a global scale.
Ramesh Hariharan, CEO and Co-Founder of Strand, expressed excitement about the collaboration's potential to leverage their collective bioinformatics expertise to elevate patient care globally.
The partnership between SOPHiA GENETICS and Strand aims to utilize their bioinformatics capabilities to enhance the accurate analysis of crucial healthcare data and promote data-driven decision-making worldwide. SOPHiA GENETICS will provide support through its decentralized SOPHiA DDM™ Platform, while Strand will contribute its curated variant databases and bioinformatics solutions expertise. Additionally, both companies will collaborate on strategic test co-development initiatives aimed at improving health outcomes in India and beyond.
Jurgi Camblong, CEO and Co-founder of SOPHiA GENETICS, emphasized the shared vision of both entities to advance patient health outcomes through precision medicine. He stressed the importance of timely and accurate data processing for healthcare organizations to enable rapid and effective treatments for conditions like cancer and rare diseases.
The SOPHiA DDM™ Platform, known for its ability to compute a wide range of genomic variants and continuously refine machine learning algorithms, will play a pivotal role in this collaboration. Together, SOPHiA GENETICS and Strand aim to enhance their value propositions through their advanced technologies and bioinformatics expertise.
Source: sophiagenetics.com
